

## Regimen Reference Order – pegylated liposomal doxorubicin desensitization

pegylated liposomal doxorubicin desensitization protocol is prescribed in combination with a pegylated liposomal doxorubicin-based protocol

To order this therapy in ARIA, refer to Additional Information below

**Planned Course:** Refer to prescribed pegylated liposomal doxorubicin-based protocol  
**Indication for Use:** Eligible patients with previous hypersensitivity reactions to pegylated liposomal doxorubicin

**Alert:** Desensitization protocol

**pegylated liposomal doxorubicin:**

- *pegylated liposomal doxorubicin is prepared in 3 separate bags with a total volume of 250 mL in BAG 1, 63 mL in BAG 2 and 250 mL in BAG 3*
- *pegylated liposomal doxorubicin must be the first chemotherapy agent administered when given in combination with another chemotherapy agent*
- *IV tubing is primed with pegylated liposomal doxorubicin (Cytotoxic)*
- *pegylated liposomal doxorubicin is administered slowly following specified rate increases. pegylated liposomal doxorubicin infusion takes approximately 5.75 hours to complete*

**CVAD:** At Provider’s Discretion

**Blood work requirements:**

❖ *Refer to prescribed pegylated liposomal doxorubicin-based protocol*

### SEQUENCE OF MEDICATION ADMINISTRATION

#### Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
<i>Refer to prescribed pegylated liposomal doxorubicin-based protocol</i>		

#### Treatment Regimen – pegylated liposomal doxorubicin desensitization

Establish primary solution 500 mL of: D5W

Drug	Dose	CCMB Administration Guideline
Antiemetics	Refer to prescribed pegylated liposomal doxorubicin-based protocol	
montelukast	10 mg	Orally <b>1 hour</b> prior to pegylated liposomal doxorubicin
cetirizine	20 mg	Orally <b>1 hour</b> prior to pegylated liposomal doxorubicin

dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes <b>1 hour</b> prior to pegylated liposomal doxorubicin <i>*Nursing Alert: pegylated liposomal doxorubicin starts 1 hour after completion of dexamethasone infusion</i>
<b>Wait 1 hour after completion of IV pre-medication(s) before starting pegylated liposomal doxorubicin</b>		
doxorubicin, peg-liposomal (pegylated liposomal doxorubicin)	1/100 <sup>th</sup> (1%) of dose (BAG 1)	IV in D5W 250 mL following the administration rates below: <b>Step 1:</b> 2 mL/hour for 15 minutes, then <b>Step 2:</b> 5 mL/hour for 15 minutes, then <b>Step 3:</b> 10 mL/hour for 15 minutes, then <b>Step 4:</b> 20 mL/hour for 15 minutes <b>Once step 4 is complete, discard remainder of bag and proceed immediately to BAG 2</b> <i>*Alert: Pharmacy to ensure final volume in bag = 250 mL</i> <i>*Alert: pegylated liposomal doxorubicin must be the first chemotherapy agent administered when given in combination with another chemotherapy agent</i> <i>*Nursing Alert: IV tubing is primed with pegylated liposomal doxorubicin</i>
	2.5% of dose (BAG 2)	IV in D5W 63 mL following the administration rates below: <b>Step 5:</b> 5 mL/hour for 15 minutes, then <b>Step 6:</b> 10 mL/hour for 15 minutes, then <b>Step 7:</b> 20 mL/hour for 15 minutes, then <b>Step 8:</b> 40 mL/hour for 15 minutes <b>Once step 8 is complete, discard remainder of bag and proceed immediately to BAG 3</b> <i>*Alert: Pharmacy to ensure final volume in bag = 63 mL</i> <i>*Nursing Alert: IV tubing is primed with pegylated liposomal doxorubicin</i>
	96.5% of dose (BAG 3)	IV in D5W 250 mL following the administration rates below: <b>Step 9:</b> 10 mL/hour for 15 minutes, then <b>Step 10:</b> 20 mL/hour for 15 minutes, then <b>Step 11:</b> 40 mL/hour for 15 minutes, then <b>Step 12:</b> 75 mL/hour until infusion is complete <i>*Alert: Pharmacy to ensure final volume in bag = 250 mL</i> <i>*Nursing Alert: IV tubing is primed with pegylated liposomal doxorubicin</i>

**In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’**

## REQUIRED MONITORING

### All Cycles

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O<sub>2</sub> saturation) at baseline and as clinically indicated
- No observation period is required after pegylated liposomal doxorubicin administration. Patient can be discharged from treatment room if stable whether they had a reaction or not
- Refer to the prescribed pegylated liposomal doxorubicin-based protocol for additional monitoring

### Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
<i>Refer to prescribed pegylated liposomal doxorubicin-based protocol</i>		

## DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity occur after discharge
- Refer to the prescribed pegylated liposomal doxorubicin-based protocol for additional instructions
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

## ADDITIONAL INFORMATION

- Oncologist must write first prescription of pegylated liposomal doxorubicin desensitization protocol
- Once the patient requires pegylated liposomal doxorubicin desensitization protocol, all subsequent pegylated liposomal doxorubicin doses must be given using pegylated liposomal doxorubicin desensitization protocol
- Refer to the prescribed pegylated liposomal doxorubicin-based protocol for additional pegylated liposomal doxorubicin information
- **ARIA ordering:** Support protocols are available under **doxo (peg-lipo) 30**, **doxo (peg-lipo) 40** and **doxo (peg-lipo) 50** in the “Desensitization” folder
- Due to the duration of treatment, administration site restrictions may be in place for pegylated liposomal doxorubicin desensitization